A Phase I Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 21 Jun 2017
At a glance
- Drugs ONC 201 (Primary)
- Indications Multiple myeloma; Solid tumours
- Focus Adverse reactions
- 14 Jun 2017 Planned End Date changed from 1 Jan 2018 to 1 Jan 2019.
- 06 Jun 2017 Results (n=17) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 25 Jan 2017 Planned End Date changed from 1 Feb 2018 to 1 Jan 2018.